Clinical Trials Browser

Hyperthermia, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fever, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Neuroendocrine Tumors

NCT05967481 2023-08-01

Evaluation of Study Experiences of Neuroendocrine Tumor Patients

Not yet recruiting

500 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05894486 2023-06-08

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Phase 2 Not yet recruiting

40 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04788927 2023-04-07

PPGL-Pred

Not yet recruiting

400 enrolled

CNSEndocrineHead & NeckNET

Head and Neck Neoplasms, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Genetic Predisposition to Disease

Clinical Trials

CardioNETPOL

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

NEUK203-13

18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

SMILE

ETP-NET

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

Endoscopic Resection for Small Rectal Neuroendocrine Tumors

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

PitNET2024

SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs

HETERERO

Evaluation of Study Experiences of Neuroendocrine Tumor Patients

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

PPGL-Pred